TCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trial Markets September 28, 2022 [ad_1] gorodenkoff TCR2 Therapeutics (NASDAQ:TCRR) stated its cell remedy gavo-cel confirmed medical profit in sufferers with mesothelin-expressing strong tumors in…
